Xiaoli Zhang, Ph.D., Kraig Labs' Chief Scientist Xiaoli Zhang, Ph.D., Kraig Labs Director of Molecular Biology ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang's leadership that are laying the foundation for t ...

ANN ARBOR, Mich., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that it is preparing to add a third production facility as part of its plans for rapid expansion of recombinant spider silk production. Over the past 18 months, Kraig Labs has significantly advanced its production model, opening two rearing centers for recombinant spider silk production. The Company is now opening a third ...

Core Insights - Kraig Biocraft Laboratories is nearing its first commercial sale of recombinant spider silk, a significant milestone for the company and the industry [1][6] - The proprietary BAM-1 recombinant spider silk is five times stronger than steel by weight, tougher than Kevlar, lighter than carbon fiber, and fully biodegradable, showcasing its exceptional properties [2][7] - The company has opened two new rearing centers in Southeast Asia, enhancing production capabilities and establishing infrastructure for year-round output [3][5] Production and Commercialization - Kraig Labs has completed one-third of the volume required for its first commercial order from a European luxury fashion house, indicating strong demand [4][6] - Ongoing discussions with a top global sportswear brand and a major athletic equipment producer suggest further integration of spider silk into high-profile products [4][6] - The establishment of separate rearing centers is part of a strategy to create a reliable and scalable supply chain to meet the growing demand for spider silk [5][6] Technological Advancements - Recent advancements include a record automated reeling run of over 250 kilograms of cocoons, optimizing the unique properties of spider silk [3][6] - The company’s focus on advanced facilities and automated processes positions it well for large-scale commercial production [5][6] - The anticipated completion of the first commercial sale is expected to launch spider silk into various industries, including defense, aerospace, textiles, and medical applications [6]

Core Insights - Kraig Biocraft Laboratories, Inc. has announced the arrival of Dr. Nirmal Kumar in Southeast Asia to support the production team at its second rearing facility, marking a significant step in the company's expansion of BAM-1 spider silk output [1][2]. Group 1: Production and Operations - Dr. Kumar will work directly with the operations team on the first production cycle at the new center, ensuring high levels of quality and efficiency [2]. - He will oversee the build-out of an expanded BAM-1 egg production center and testing lab, which are essential for ongoing scale-up and maintaining production continuity across multiple rearing centers [3]. - The new facilities are part of the company's long-term commercialization strategy to ramp up BAM-1 production to meet growing demand [3]. Group 2: Market Opportunities - Dr. Kumar will explore opportunities with secondary processing providers in the region, including spinners for downstream applications of recombinant spider silk [4]. - The company is in discussions with a potential customer regarding a custom order of spider silk thread, which is crucial for demonstrating the versatility and scalability of BAM-1 in specialty textile markets [4]. Group 3: Leadership and Strategy - The presence of Dr. Kumar on-site provides invaluable expertise at a critical stage for the second rearing center, strengthening the current BAM-1 production cycle and setting the stage for future expansion and processing partnerships [5]. - The company's ability to execute on both upstream production and downstream processing highlights its unique position at the intersection of biotechnology and traditional sericulture [5].

Core Insights - Kraig Biocraft Laboratories, Inc. has fully operationalized its second production rearing center in Southeast Asia, enhancing its spider silk technology capabilities [1][5] - The establishment of two active production facilities allows for continuous rearing cycles of specialized recombinant spider silk silkworms, increasing resilience and scalability [2][5] - The company has expanded its breeding program with new genetic lines, which are expected to improve production efficiencies [3][5] Production and Operations - The dual-site capacity is designed to avoid past bottlenecks and create efficient redundancy, marking a significant advancement in sustained production [4][5] - Active teams are working with established parental lines for BAM-1 production hybrids and three additional parental lines introduced earlier this summer [3][5] Strategic Goals - The operational milestone of the second rearing center strengthens the foundation of the company's spider silk production platform, essential for scaling production and meeting market demand [5] - The company aims to diversify its breeding program and accelerate the development of next-generation hybrids to cater to growing demand from various markets and industries [5]

Core Insights - Kraig Biocraft Laboratories, Inc. has launched its first full production cycle at a new facility in Southeast Asia, established in collaboration with a government agency, aimed at enhancing spider silk output and market readiness [1][2] Group 1: Production and Capacity - The new facility is designed to expand capacity and ensure operational security as the company scales up its recombinant spider silk manufacturing [2] - The inaugural production cycle will involve rearing parent lines for the BAM-1 spider silk hybrid and several new transgenic lines introduced in the first half of 2025, which are expected to yield higher silk quality and robustness [3] Group 2: Strategic Importance - The facility is a critical step in enhancing production capabilities, allowing the company to maintain quality and consistency in its spider silk products while supporting its growth strategy [4] - The production cycle is expected to lay the groundwork for future expansion and readiness for delivering high-grade fibers, continuing the scaling of proprietary silk technology [4] Group 3: Company Overview - Kraig Biocraft Laboratories is recognized as a leading developer of genetically engineered spider silk-based fiber technologies, with significant breakthroughs impacting the global textile industry [6]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully produced over 250 kilograms of reeled raw recombinant spider silk using automated equipment, setting a new single run record and enhancing quality, yield, and scalability of production [1][4][5] Group 1: Production Improvements - The use of automated reeling equipment allows for fine-tuning the reeling process specifically for spider silk, optimizing fiber consistency and maximizing silk output [3][4] - Automated reeling replaces conventional multi-end systems, significantly improving throughput, labor efficiency, and downstream silk quality [4] Group 2: Strategic Developments - Recent operational momentum includes the expansion of rearing capacity in Asia and the development of new spider silk strains, supporting the mission to bring eco-friendly spider silk fibers to market [5][7] - The compatibility of Kraig Labs' proprietary spider silk cocoons with advanced reeling systems is central to building a vertically integrated production model for spider silk at scale [4][5]

Core Insights - Kraig Biocraft Laboratories, Inc. has signed a multi-year agreement with a Southeast Asian government agency to enhance its recombinant spider silk production capabilities [1][2] - This agreement is a significant milestone in the company's efforts to commercialize next-generation biomaterials, providing access to essential resources for scaling production [2][3] - The company plans to take possession of a new facility and begin operations in early August, which will facilitate faster and more efficient large-scale commercialization [3] Company Overview - Kraig Biocraft Laboratories is a leading developer of genetically engineered spider silk-based fiber technologies, with notable scientific breakthroughs impacting the global textile industry [5] - The company has established itself as a world leader in spider silk technology, focusing on innovative applications in various sectors [5]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed the first rearing cycles for three new recombinant spider silk production strains, demonstrating strong performance across key production metrics [1][2][3] - The transition from R&D to field production marks a critical milestone in the company's strategy to deploy advanced spider silk genetics rapidly [2][3] - The company is focused on expanding egg inventories and preparing for a second rearing cycle, indicating a robust production roadmap [3][4] Group 1 - The new strains have shown excellent vitality and alignment with large-scale production targets, validating the company's development pipeline [2][3] - The successful launch of these strains serves as proof of concept for future generations of advanced transgenic silks currently under development [3][4] - The company aims to build a cost-effective and scalable spider silk production platform, setting the stage for deploying advanced technologies with confidence [4] Group 2 - Kraig Labs is aggressively ramping up egg multiplication efforts to support the next generation of production cycles [3] - The company is recognized as a leader in genetically engineered spider silk-based fiber technologies, with significant implications for the global textile industry [6]

Core Insights - Kraig Biocraft Laboratories, Inc. has received a business license to operate in Cambodia, marking a significant step in its strategy to scale up and diversify production capabilities in response to its 2025 expansion initiatives [1][2][3] Group 1: Expansion Strategy - The decision to launch operations in Cambodia is based on the positive momentum achieved through expanded production efforts this year [2] - The Cambodian business license is expected to support the company's goals of increasing production capacity while diversifying its production footprint [3] Group 2: Production and Technology - The new location in Cambodia is seen as an opportunity to enhance the company's spider silk production scale, leveraging the right combination of climate and infrastructure [3] - Kraig Labs continues to invest in research and infrastructure to advance the performance and scalability of its proprietary recombinant spider silk technologies [3][4] Group 3: Industry Position - Kraig Labs is recognized as a leader in genetically engineered spider silk-based fiber technologies, with significant breakthroughs that have implications for the global textile industry [5][6]